2001-2003,capshine.co.uk,Automotive , Replacement Parts , Fuel System,For,INJECTOR,4.7L,NEW,/menses104922.html,53032145AA,TRUCK,FUEL,JEEP,DODGE,$13 2001-2003,capshine.co.uk,Automotive , Replacement Parts , Fuel System,For,INJECTOR,4.7L,NEW,/menses104922.html,53032145AA,TRUCK,FUEL,JEEP,DODGE,$13 $13 FUEL INJECTOR 53032145AA NEW For 2001-2003 JEEP DODGE TRUCK 4.7L Automotive Replacement Parts Fuel System FUEL INJECTOR New sales 53032145AA NEW For JEEP DODGE TRUCK 2001-2003 4.7L FUEL INJECTOR New sales 53032145AA NEW For JEEP DODGE TRUCK 2001-2003 4.7L $13 FUEL INJECTOR 53032145AA NEW For 2001-2003 JEEP DODGE TRUCK 4.7L Automotive Replacement Parts Fuel System

FUEL INJECTOR OFFicial mail order New sales 53032145AA NEW For JEEP DODGE TRUCK 2001-2003 4.7L

FUEL INJECTOR 53032145AA NEW For 2001-2003 JEEP DODGE TRUCK 4.7L

$13

FUEL INJECTOR 53032145AA NEW For 2001-2003 JEEP DODGE TRUCK 4.7L

|||

Product description


SKU: FIJP001USAM
OE Number For Reference: 53032145AA
Compatible with: Fit For 2001-2003 JEEP DODGE TRUCK 4.7L V8 Grand Cherokee Ram 1500 Durango Dakota.
Warranty: One year.
About item's Color and quantity: Just like the pictures. "br"Please make sure the OE and car model in our listing are the same with car part you need. "br"Item condition: 100% NEW "br"Package:PackIng the item with white foam and tape. "br"The item need 7 to 20 days to arrive at your place. If you have any question,please feel free to contact us.Thank you for your supporting.

FUEL INJECTOR 53032145AA NEW For 2001-2003 JEEP DODGE TRUCK 4.7L

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA